Sanofi has received orphan designation from the European Medicines Agency (EMA) for rilzabrutinib, a reversible covalent ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

A new study published in the Journal of American Medical Association found that Rilzabrutinib decreased itching and hives ...

Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at ...

Rilzabrutinib was added to Sanofi’s pipeline with the acquisition of Principia Biopharma. The candidate is also being developed in mid-stage studies for other immune-mediated diseases like ...

Rilzabrutinib is currently under regulatory review in the US and the EU, with a US Food and Drug Administration target action date of August 29, 2025. Dietmar Berger, MD, PhD ...

Rilzabrutinib is an oral, small molecule, reversible covalent inhibitor of Bruton’s tyrosine kinase (BTK) that modulates immune-mediated processes in ITP.

SAN DIEGO — Rilzabrutinib treatment led to rapid, stable and durable platelet responses among patients with relapsed immune thrombocytopenia, according to data presented at ASH Annual Meeting ...

SAN DIEGO — Patients with moderate to severe asthma who were treated with rilzabrutinib showed a reduction in loss of asthma control events, according to a study presented at the American ...

Rilzabrutinib also led to significant improvements in bleeding (based on the Immune Thrombocytopenic Purpura Bleeding Score), with a mean change from baseline at week 25 of –0.04 with ...

Rilzabrutinib will continue to be investigated in a phase 3 trial for the treatment of immune thrombocytopenia and in a phase 2 study for the autoimmune condition lgG4-related disease.